Protocol for the Examination of Prostate Needle Biopsies From Patients With Carcinoma of the Prostate Gland: Case Level Reporting

Version: 1.0.0.1
Protocol Posting Date: November 2021
The use of this protocol is recommended for clinical care purposes but is not required for accreditation purposes.

This protocol may be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
<td>Includes specimens designated needle biopsy</td>
</tr>
<tr>
<td>Tumor Type</td>
<td>Description</td>
</tr>
<tr>
<td>Carcinoma</td>
<td>Includes all adenocarcinomas and histologic variants, neuroendocrine carcinomas, and others</td>
</tr>
</tbody>
</table>

The following should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transurethral resection of the prostate (TURP) and enucleation specimens (simple or subtotal prostatectomy) (consider Prostate TURP protocol)</td>
</tr>
<tr>
<td>Radical Prostatectomy (consider Prostate Radical Prostatectomy protocol)</td>
</tr>
<tr>
<td>Cytologic specimens</td>
</tr>
<tr>
<td>Tumor Type</td>
</tr>
<tr>
<td>Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols)</td>
</tr>
<tr>
<td>Sarcoma (consider the Soft Tissue protocol)</td>
</tr>
</tbody>
</table>

Authors
Gladell P. Paner, MD*; John R. Srigley, MD*; Jason Pettus, MD; Giovanna Angela Giannico, MD; Joseph Sirintrapun, MD; Lara R. Harik, MD.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.
* Denotes primary author.
Accreditation Requirements
The use of this case summary is recommended for clinical care purposes but is not required for accreditation purposes. The core and conditional data elements are routinely reported. Non-core data elements are indicated with a plus sign (+) to allow for reporting information that may be of clinical value.

Summary of Changes

v 1.0.0.1
- The CAP made no changes to Cancer Protocol content. We updated metadata only for the electronic Cancer Checklists (eCC), requiring a version number change for the Word and PDF Cancer Protocols.
Reporting Template

Protocol Posting Date: November 2021
Select a single response unless otherwise indicated.

CASE SUMMARY: (Prostate Gland: Needle Biopsy (Case Level))

CASE SUMMARY
This case summary is recommended for reporting biopsy specimens, but is not required for accreditation purposes

Procedure (Note A) (select all that apply)
___ Systematic biopsy
___ Targeted biopsy
___ Other (specify): _________________

POSITIVE SPECIMEN(S) OR ZONE(S)
Specimen ID may be entered with the selected location
+Positive Specimen Location(s) (select all that apply)
___ Right: _________________
   ___ Right Base (RB): __________________________
   ___ Right Base Lateral (RBL): __________________________
   ___ Right Base Medial (RBM): __________________________
   ___ Right Mid (RM): __________________________
   ___ Right Mid Lateral (RML): __________________________
   ___ Right Mid Medial (RMM): __________________________
   ___ Right Apex (RA): __________________________
   ___ Right Apex Lateral (RAL): __________________________
   ___ Right Apex Medial (RAM): __________________________
   ___ Right Transition Zone (RTZ): __________________________
___ Left: _________________
   ___ Left Base (LB): __________________________
   ___ Left Base Lateral (LBL): __________________________
   ___ Left Base Medial (LBM): __________________________
   ___ Left Mid (LM): __________________________
   ___ Left Mid Lateral (LML): __________________________
   ___ Left Mid Medial (LMM): __________________________
   ___ Left Apex (LA): __________________________
   ___ Left Apex Lateral (LAL): __________________________
   ___ Left Apex Medial (LAM): __________________________
   ___ Left Transition Zone (LTZ): __________________________
___ Other Transrectal Ultrasound (TRUS) lesion: __________________________
___ MRI-guided Biopsy: __________________________
___ Other (specify): __________________________

Histologic Type (Note B) (select all that apply)
___ Acinar adenocarcinoma
___ Ductal adenocarcinoma
___ Small-cell neuroendocrine carcinoma
___ Isolated intraductal carcinoma
___ Other histologic type not listed (specify): __________________________
Histologic Type Comments: _________________

Histologic Grade (Note C)

Highest Gleason Score

This applies in cases where there are 2 or more sites (containers) that contain cancer with different Gleason Scores.

Highest Grade

- Not applicable: _________________
- Cannot be assessed: _________________
- Grade group 1 (Gleason Score 3 + 3 = 6)
- Grade group 2 (Gleason Score 3 + 4 = 7)
- Grade group 3 (Gleason Score 4 + 3 = 7)
- Grade group 4 (Gleason Score 4 + 4 = 8)
- Grade group 4 (Gleason Score 3 + 5 = 8)
- Grade group 4 (Gleason Score 5 + 3 = 8)
- Grade group 5 (Gleason Score 4 + 5 = 9)
- Grade group 5 (Gleason Score 5 + 4 = 9)
- Grade group 5 (Gleason Score 5 + 5 = 10)

Site(s) with Highest Gleason Score (select all that apply)

- Right: _________________
  - Right Base (RB): _________________
  - Right Base Lateral (RBL): _________________
  - Right Base Medial (RBM): _________________
  - Right Mid (RM): _________________
  - Right Mid Lateral (RML): _________________
  - Right Mid Medial (RMM): _________________
  - Right Apex (RA): _________________
  - Right Apex Lateral (RAL): _________________
  - Right Apex Medial (RAM): _________________
  - Right Transition Zone (RTZ): _________________
- Left: _________________
  - Left Base (LB): _________________
  - Left Base Lateral (LBL): _________________
  - Left Base Medial (LBM): _________________
  - Left Mid (LM): _________________
  - Left Mid Lateral (LML): _________________
  - Left Mid Medial (LMM): _________________
  - Left Apex (LA): _________________
  - Left Apex Lateral (LAL): _________________
  - Left Apex Medial (LAM): _________________
  - Left Transition Zone (LTZ): _________________
- Other Transrectal Ultrasound (TRUS) lesion: _________________
- MRI-guided Biopsy: _________________
- Other (specify): _________________

Overall Grade

Systematic Biopsy Overall Grade

- Not applicable
- Cannot be assessed: _________________
- Grade group 1 (Gleason Score 3 + 3 = 6)
- Grade group 2 (Gleason Score 3 + 4 = 7)
**Percentage of Pattern 4**

- Less than or equal to 5%
- 6 - 10%
- 11 - 20%
- 21 - 30%
- 31 - 40%
- Greater than 40%

Grade group 3 (Gleason Score 4 + 3 = 7)

**Percentage of Pattern 4**

- Less than 61%
- 61 - 70%
- 71 - 80%
- 81 - 90%
- Greater than 90%

Grade group 4 (Gleason Score 4 + 4 = 8)

Grade group 4 (Gleason Score 3 + 5 = 8)

Grade group 4 (Gleason Score 5 + 3 = 8)

Grade group 5 (Gleason Score 4 + 5 = 9)

Grade group 5 (Gleason Score 5 + 4 = 9)

Grade group 5 (Gleason Score 5 + 5 = 10)

**Global**

**Composite**

---

**Targeted Biopsy Grade (may be repeated according to the number of targeted biopsy sites)**

- Not applicable
- Cannot be assessed: ________________

Grade group 1 (Gleason Score 3 + 3 = 6)

Grade group 2 (Gleason Score 3 + 4 = 7)

**Percentage of Pattern 4**

- Less than or equal to 5%
- 6 - 10%
- 11 - 20%
- 21 - 30%
- 31 - 40%
- Greater than 40%

Grade group 3 (Gleason Score 4 + 3 = 7)

**Percentage of Pattern 4**

- Less than 61%
__ 61 - 70%
__ 71 - 80%
__ 81 - 90%
__ Greater than 90%
__ Grade group 4 (Gleason Score 4 + 4 = 8)
__ Grade group 4 (Gleason Score 3 + 5 = 8)
__ Grade group 4 (Gleason Score 5 + 3 = 8)
__ Grade group 5 (Gleason Score 4 + 5 = 9)
__ Grade group 5 (Gleason Score 5 + 4 = 9)
__ Grade group 5 (Gleason Score 5 + 5 = 10)

+Percentage of Pattern 4 (applicable for Targeted Biopsy Gleason Score 8 and above): ________________ %

+Percentage of Pattern 5 (applicable for Targeted Biopsy Gleason Score 8 and above): ________________ %

+Targeted Biopsy Identifier: ________________

+Combined Systematic and Targeted Biopsy Grade
__ Cannot be assessed: ________________
__ Grade group 1 (Gleason Score 3 + 3 = 6)
__ Grade group 2 (Gleason Score 3 + 4 = 7)

Percentage of Pattern 4
__ Less than or equal to 5%
__ 6 - 10%
__ 11 - 20%
__ 21 - 30%
__ 31 - 40%
__ Greater than 40%
__ Grade group 3 (Gleason Score 4 + 3 = 7)

Percentage of Pattern 4
__ Less than 61%
__ 61 - 70%
__ 71 - 80%
__ 81 - 90%
__ Greater than 90%
__ Grade group 4 (Gleason Score 4 + 4 = 8)
__ Grade group 4 (Gleason Score 3 + 5 = 8)
__ Grade group 4 (Gleason Score 5 + 3 = 8)
__ Grade group 5 (Gleason Score 4 + 5 = 9)
__ Grade group 5 (Gleason Score 5 + 4 = 9)
__ Grade group 5 (Gleason Score 5 + 5 = 10)

+Percentage of Pattern 4 (applicable for Combined Systematic and Targeted Biopsy Gleason Score 8 and above): ________________ %

+Percentage of Pattern 5 (applicable for Combined Systematic and Targeted Biopsy Gleason Score 8 and above): ________________ %
Intraductal Carcinoma (IDC) (Note D)
___ Not identified
___ Present
    IDC Incorporated into Grade
    ___ Yes
    ___ No
    ___ Cannot be determined (explain): ____________________

Cribiform Glands (applicable to Gleason Score 7 or 8 cancer only)
___ Not applicable
___ Not identified
___ Present: ____________________
___ Equivocal (explain): ____________________
___ Cannot be determined: ____________________

Treatment Effect (select all that apply)
___ No known presurgical therapy
___ Not identified
___ Treatment effect present and de novo cancer present: ____________________
___ Radiation therapy effect present: ____________________
___ Hormonal therapy effect present: ____________________
___ Other therapy effect(s) present (specify): ____________________
___ Cannot be determined: ____________________

Tumor Quantitation (Note E)
Total Number of Cores
___ Specify number: ____________________
___ Cannot be determined

Number of Positive Cores
___ Specify number: ____________________
___ Cannot be determined

+Tumor Measurement Technique (select all that apply)
___ Single continuous focus
___ Consider multiple foci as continuous tumor
___ Consider multiple foci as discontinuous tumor

Greatest Percentage of Core Involvement by Cancer in Any Core
___ Less than 1%
___ 1 - 5%
___ 6 - 10%
___ 11 - 20%
___ 21 - 30%
___ 31 - 40%
___ 41 - 50%
___ 51 - 60%
___ 61 - 70%
<table>
<thead>
<tr>
<th>Percentage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>71 - 80%</td>
<td></td>
</tr>
<tr>
<td>81 - 90%</td>
<td></td>
</tr>
<tr>
<td>Greater than 90%</td>
<td></td>
</tr>
<tr>
<td>Cannot be determined (explain):</td>
<td></td>
</tr>
</tbody>
</table>

Specify Site(s) (select all that apply)

<table>
<thead>
<tr>
<th>Site</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right:</td>
<td></td>
</tr>
<tr>
<td>Right Base (RB):</td>
<td></td>
</tr>
<tr>
<td>Right Base Lateral (RBL):</td>
<td></td>
</tr>
<tr>
<td>Right Base Medial (RBM):</td>
<td></td>
</tr>
<tr>
<td>Right Mid (RM):</td>
<td></td>
</tr>
<tr>
<td>Right Mid Lateral (RML):</td>
<td></td>
</tr>
<tr>
<td>Right Mid Medial (RMM):</td>
<td></td>
</tr>
<tr>
<td>Right Apex (RA):</td>
<td></td>
</tr>
<tr>
<td>Right Apex Lateral (RAL):</td>
<td></td>
</tr>
<tr>
<td>Right Apex Medial (RAM):</td>
<td></td>
</tr>
<tr>
<td>Right Transition Zone (RTZ):</td>
<td></td>
</tr>
<tr>
<td>Left:</td>
<td></td>
</tr>
<tr>
<td>Left Base (LB):</td>
<td></td>
</tr>
<tr>
<td>Left Base Lateral (LBL):</td>
<td></td>
</tr>
<tr>
<td>Left Base Medial (LBM):</td>
<td></td>
</tr>
<tr>
<td>Left Mid (LM):</td>
<td></td>
</tr>
<tr>
<td>Left Mid Lateral (LML):</td>
<td></td>
</tr>
<tr>
<td>Left Mid Medial (LMM):</td>
<td></td>
</tr>
<tr>
<td>Left Apex (LA):</td>
<td></td>
</tr>
<tr>
<td>Left Apex Lateral (LAL):</td>
<td></td>
</tr>
<tr>
<td>Left Apex Medial (LAM):</td>
<td></td>
</tr>
<tr>
<td>Left Transition Zone (LTZ):</td>
<td></td>
</tr>
</tbody>
</table>

MRI-guided Biopsy: _________________
Other Transrectal Ultrasound (TRUS) lesion: _________________
Other (specify): _________________

Greatest Length of Core Involvement by Cancer in Any Core in Millimeters (mm):

mm

Specify Site(s) (select all that apply)

<table>
<thead>
<tr>
<th>Site</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right:</td>
<td></td>
</tr>
<tr>
<td>Right Base (RB):</td>
<td></td>
</tr>
<tr>
<td>Right Base Lateral (RBL):</td>
<td></td>
</tr>
<tr>
<td>Right Base Medial (RBM):</td>
<td></td>
</tr>
<tr>
<td>Right Mid (RM):</td>
<td></td>
</tr>
<tr>
<td>Right Mid Lateral (RML):</td>
<td></td>
</tr>
<tr>
<td>Right Mid Medial (RMM):</td>
<td></td>
</tr>
<tr>
<td>Right Apex (RA):</td>
<td></td>
</tr>
<tr>
<td>Right Apex Lateral (RAL):</td>
<td></td>
</tr>
<tr>
<td>Right Apex Medial (RAM):</td>
<td></td>
</tr>
<tr>
<td>Right Transition Zone (RTZ):</td>
<td></td>
</tr>
<tr>
<td>Left:</td>
<td></td>
</tr>
<tr>
<td>Left Base (LB):</td>
<td></td>
</tr>
<tr>
<td>Left Base Lateral (LBL):</td>
<td></td>
</tr>
</tbody>
</table>

Replaced by version 1.1.0.0 on September 20, 2023, Obsolete as of June 2024 (8 months after newest release date)
___ Left Base Medial (LBM): _________________
___ Left Mid (LM): _________________
___ Left Mid Lateral (LML): _________________
___ Left Mid Medial (LMM): _________________
___ Left Apex (LA): _________________
___ Left Apex Lateral (LAL): _________________
___ Left Apex Medial (LAM): _________________
___ Left Transition Zone (LTZ): _________________
___ Other Transrectal Ultrasound (TRUS) lesion: _________________
___ MRI-guided Biopsy: _________________
___ Other (specify): _________________

+Percentage of Total Prostatic Tissue Involved by Tumor: _________________ %

+Total Linear Millimeters (mm) of Carcinoma: _________________ mm

+Total Linear Millimeters (mm) of Needle Core Tissue: _________________ mm

Periprostatic Fat Invasion (report if identified in specimen) (Note F)
___ Not identified
___ Present: _________________
___ Equivocal (explain): _________________
___ Cannot be determined: _________________

Seminal Vesicle Invasion (report if seminal vesicle is submitted) (Note F)
___ Not identified
___ Present: _________________
___ Equivocal (explain): _________________
___ Cannot be determined: _________________

+Lymphovascular Invasion
___ Not identified
___ Present
___ Equivocal (explain): _________________
___ Cannot be determined: _________________

+Perineural Invasion (Note G)
___ Not identified
___ Present

+Additional Findings (select all that apply)
___ None identified: _________________
___ Atypical intraductal proliferation (AIP) (Note H)
___ High-grade prostatic intraepithelial neoplasia (PIN) (Note I): _________________
___ Atypical small acinar proliferation / small focus of atypical glands (ASAP / ATYP): _________________
___ Inflammation (specify type): _________________
___ Other (specify): _________________

Replaced by version 1.1.0.0 on September 20, 2023, Obsolete as of June 2024 (8 months after newest release date)
Replaced by version 1.1.0.0 on September 20, 2023, Obsolete as of June 2024 (8 months after newest release date)


**Explanatory Notes**

### A. Level of Biopsy Reporting (Specimen or Case)

In a prostate biopsy case, 12 to 14 cores are generally received; however in some cases, 15 or more cores are may be provided depending on the protocols used. Submission will include systematic mapping biopsies (transrectal or transperineal) with or without MRI-targeted biopsy(ies) (also see Figure 1). In situation where there is a high clinical suspicion of a high-grade or high stage disease that is suboptimal for active surveillance, a conservative biopsy sampling of the prostate is performed with fewer number of cores (<12 cores).

![Diagram of prostate biopsy reporting](image)

**Figure 1.** Schematic overview of reporting systematic and targeted biopsies.

In the situation, for example, where 12 cores from systematic sampling are submitted, ideally these should be received in 12 separate site-specific labeled containers (1 core per container from each specific site). However, occasionally these 12 cores may also be received in 6 containers each with 2 cores with typical sextant designations or 6 cores in each of 2 containers labeled left and right (more than 1 core per container from combined sites). It is also not uncommon for one specific site to have more than 1 core sampled (more than 1 core per container from one specific site). In addition to systematic biopsies, MRI-guided biopsies of
suspicious abnormalities are commonly being performed. With respect to technical quality, single-core site-specific labeled submission is ideal, but 2 core submission is also acceptable. When more than 2 cores are submitted in a single container, there is an increased likelihood of fragmentation.

The reporting of prostate biopsies may be done at specimen and case level.\textsuperscript{10} It is recommended that Gleason grading should be assigned to each individual biopsy site.\textsuperscript{9,11,12,13,14} For single cores in individual containers representing different sites, this recommendation is not a problem. When there is more than 1 core received in one container, individual core reporting is recommended if the cores are separately labeled as to their specific location with colored inks.

In the situation of systematic biopsy where there are multiple unidentified intact cores submitted in 1 specimen container and each shows cancer, individual core reporting maybe attempted but this is optional. In MRI-targeted biopsy, grade should be assigned for each individual suspicious lesion.

Two optional case summaries are provided for prostate biopsies with cancer. One is a \textit{specimen-level summary}, which would be used for each positive specimen. In a case where 6 of 12 specimens show prostate cancer, 6 specimen summaries would be used. A \textit{case-level summary} is also provided, which can be used in conjunction with the specimen level summaries or on its own. In the latter situation, a simple line diagnosis documenting the Gleason grades, score, extent measurements, and other relevant observations should be provided for each positive specimen.

The minimum required reporting is at the specimen level, and more granular reporting would be considered optional. This approach is important as it takes into account workload considerations. In workload measurement systems (at least those based on the CPT system), the units of work are the specimens and not the individual pieces or fragments that constitute a single specimen.

References
B. Histologic Type
This protocol applies only to invasive adenocarcinomas of the prostate gland.\textsuperscript{1} Carcinomas other than adenocarcinoma are exceptionally uncommon, accounting for less than 1% of prostatic tumors. The protocol does not apply to pure squamous cell carcinoma, basal cell carcinoma, urothelial carcinoma, small cell neuroendocrine carcinoma, and large cell neuroendocrine carcinoma. If these rare subtypes of carcinoma, however, are mixed with acinar type adenocarcinoma, the protocol may be used.

Some adenocarcinoma variants have percentage cut-offs to render their diagnosis. Since examination of the entire tumor is not amenable in biopsy, a descriptive approach in their diagnosis should also be considered (e.g. adenocarcinoma with mucinous features, adenocarcinoma with signet ring-like cell features).

References

C. Histologic Grade
Gleason Score
The Gleason grading system is recommended for use in all prostatic specimens containing adenocarcinoma, with the exception of those showing treatment effects, usually in the setting of hormonal ablation and radiation therapy.\textsuperscript{1,2,3} Readers are referred to the recommendations of three ISUP consensus conferences and the GUPS position paper dealing with the contemporary usage of the Gleason system in biopsy specimens (also see Figure 2).\textsuperscript{4,5,6,7} The Gleason score in biopsy is an important parameter used in active surveillance criteria and nomograms, such as the Kattan nomograms, and the Partin tables, which guide individual treatment decisions.\textsuperscript{8,9,10,11}

In needle biopsy specimens, Gleason score is the sum of the primary (most predominant) Gleason grade and worst (of the non-predominant) Gleason grade. Where no secondary Gleason grade exists, the primary
Gleason grade is doubled to arrive at a Gleason score. The primary and secondary grades should be reported in addition to the Gleason score, that is, Gleason score 7(3+4) or 7(4+3).

**Figure 2.** 2015 modified ISUP Gleason schematic diagram.

It is recommended that Gleason scores be assigned for each separately identified needle biopsy site, including for each MRI-targeted lesion. If multiple cores in a specimen container are not separately designated, a Gleason score can be assigned for that specimen.

In needle biopsy specimens where there is a minor secondary component (less than 5% of tumor) and where the secondary component is of higher grade, the latter should be reported. For instance, a case showing more than 95% Gleason pattern 3 and less than 5% Gleason pattern 4 should be reported as Gleason score 7(3+4). Conversely, if a minor secondary pattern is of lower grade, it need not be reported. For instance, where there is greater than 95% Gleason pattern 4 and less than 5% Gleason pattern 3, the score should be reported as Gleason score 8(4+4).

In needle biopsy specimens where more than 2 patterns are present, and the worst grade is neither the predominant nor the secondary grade, the predominant and highest grade should be chosen to arrive at a score (eg, 75% pattern 3, 20-25% pattern 4, <5% pattern 5 is scored as 3+5=8). The above rules apply to
both specimen-level and case-level reporting.

Another recommendation is that the percentage of pattern 4 should be reported in all Gleason score 7(3+4, 4+3) cases. This measurement further stratifies Gleason score 7 and allows identification of cases with limited pattern 4 (e.g., <10%) or extensive pattern 4 (e.g., >80%). This has practical importance since selected patients with Gleason score 7(3+4) but small amounts of pattern 4 (≤ 10%) may be eligible for active surveillance. A method recommended for reporting of Gleason pattern 4 is either 5% or less or 10% or less and 10% increments thereafter.

In limited cancer focus (<10% involvement of a core), grading and reporting of percentage Gleason pattern 4 should be made with caution and a comment should be made stating that the focus is too small to accurately assign a percent of Gleason pattern 4.

It is now recognized that Gleason pattern 4 has four basic architectures in cribriform, fused, poorly-formed and glomeruloid glands. Among these architectures, cribriform has been shown to be an independent predictor of poorer outcome particularly in Gleason score 7 tumors. It is now recommended to report the presence of cribriform gland in biopsies with Gleason pattern 4 cancer. There are recent attempts to standardize the definition of cribriform pattern.

The presence treatment effects to cancer should be reported and is important especially if Gleason grading is rendered not applicable. It should be recognized that in post-treatment settings, grading may still be applied for prostate cancers lacking treatment effects particularly on the new onset (de novo) cancers.

**Grade Group**

It is recognized that contemporary Gleason scores can be grouped into 5 prognostic categories, Grade groups 1-5. This grade grouping has also been subsequently validated by other independent studies in surgical cohorts showing significant correlation with outcome. The new grade grouping has been endorsed by ISUP, GUPS and in the 2016 WHO classification. The grade group is also referred to as ISUP grade or WHO grade in other publications. The grade group should be reported in parallel with the Gleason score.

<table>
<thead>
<tr>
<th>Grade Group</th>
<th>Gleason Score</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Less than or equal to 6</td>
<td>Only individual discrete well-formed glands</td>
</tr>
<tr>
<td>2</td>
<td>3+4=7</td>
<td>Predominantly well-formed glands with lesser component of poorly formed/fused/cribriform glands</td>
</tr>
<tr>
<td>3</td>
<td>4+3=7</td>
<td>Predominantly poorly formed/fused/cribriform glands with lesser component (#) of well-formed glands</td>
</tr>
<tr>
<td>4</td>
<td>4+4=8</td>
<td>Only poorly formed/fused/cribriform glands</td>
</tr>
<tr>
<td></td>
<td>3+5=8</td>
<td>Predominantly well-formed glands and lesser component (##) lacking glands (or with necrosis)</td>
</tr>
<tr>
<td></td>
<td>5+3=8</td>
<td>Predominantly lacking glands (or with necrosis) and lesser component (##) of well-formed glands</td>
</tr>
<tr>
<td>5</td>
<td>9-10</td>
<td>Lack gland formation (or with necrosis) with or without poorly formed/fused/cribriform glands (#)</td>
</tr>
</tbody>
</table>

#For cases with greater than 95% poorly formed/fused/cribriform glands on a core or at radical prostatectomy, the component of less than 5% well-formed glands is not factored into the grade; should therefore be graded as grade group 4.

##Poorly formed/fused/cribriform glands can be a more minor component.
**Highest, Composite and Global Gleason Scores**

In case level reporting for systematic biopsy, grade can be recorded as highest grade, composite grade, and global grade.\(^{6,7,24,25,26}\) Both composite and global grades are aggregate grading of multiple positive sites. Composite grade takes into consideration the contiguous topographic location of positive sites representing the presumed dominant nodule whereas global grade considers all positive sites regardless of topography (also see Figure 3). Composite grade also considers the similarity of tumor morphology in the adjacent positive cores and extent of involvement of each positive core. Use of composite grade avoids dilution of the dominant nodule by separate lower grade cancers in other cores. Composite grade has been shown to correlate better with the grade in radical prostatectomy.

In targeted biopsies, the grade of the sampled lesion is already equivalent to the composite grade and thus, global grade is not applicable in this setting.

In cases when different scores are found in the systematic and targeted biopsies, there is an option to report a global grade or composite grade factoring in both systematic and targeted biopsies.

---

**Figure 3.** Example of a case wherein global, composite and highest grades are not similar.

**References**


D. Intraductal Carcinoma (IDC)
The presence of intraductal carcinoma (IDC) is important to record in biopsy since it has independent prognostic significance. IDC is uncommon in needle biopsies and when present is usually found within invasive tumor. Pure IDC is rare in needle biopsies. It is important to distinguish IDC from high-grade prostatic intraepithelial neoplasia (PIN) and atypical intraductal proliferation (AIP). IDC is strongly associated with high Gleason score and high-volume tumor in radical prostatectomies and with metastatic disease.

Both ISUP and GUPS recommend that Gleason scores or grade groups should not be assigned to pure IDC. However, there is controversy when grading invasive cancer with concomitant IDC. ISUP recommends incorporating IDC in determining the grade while GUPS recommends not to include IDC in determining the grade. It is recommended to specify which of these two grading approaches is applied when grading invasive cancer with concomitant IDC.

Distinction between IDC and invasive cribriform or comedonecrosis patterns should be based on morphological examination. In the grading approach where IDC is not incorporated in grading, immunohistochemistry for basal cells can be used if the results will change the grade.

References
6. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; and the Grading Committee The 2014 International Society of Urological Pathology (ISUP) Consensus


E. Quantitation of Tumor

Studies have shown prostate cancer volume is a prognostic factor, although data are conflicting as to its independent prognostic significance.12346 For needle core biopsy specimens, the number of positive cores out of the total number of cores should always be reported, except in situations where fragmentation precludes accurate counting. The estimated percentage of prostatic tissue involved by tumor and/or the linear millimeters of the tumor should also be reported. Reporting of the positive core with the greatest percentage of tumor is an option since in some active surveillance (AS) protocols, the presence of any cores with >50% involvement is an exclusion criterion.6

It is not uncommon that a core is discontinuously involved by cancer foci.789 One practical consideration is how to record discontinuous areas of tumor involvement. For instance, in a 20-mm core with 5% involvement at each end, the amount may be recorded as 5% + 5% = 10% involvement or 100% involvement in a discontinuous fashion even though there is only 2 mm of actual tumor length. The pattern of reporting may actually exclude a patient from an AS protocol. In such situations, it may be worthwhile reporting discontinuous involvement by both including (considering multiple foci as discontinuous tumor) and subtracting (considering multiple foci as continuous tumor); for example, in the 20-mm core, there are discontinuous foci of adenocarcinoma spanning a distance of 20 mm (100% linear extent) and measuring 1+1=2 mm (10% linear extent). Most studies have also shown that recording the cancer length from one end to the other correlates better with radical prostatectomy findings and prognostic outcomes than subtracting the intervening benign prostate tissue. These findings are supported by studies that showed that 75% to 80% of discontinuous cancer foci in prostate biopsy cores might represent the same tumor focus.7

References


F. Local Invasion in Needle Biopsies

Occasionally in needle biopsies, periprostatic fat is present that is involved by tumor. Fat is rare within the prostate parenchyma and its presence in biopsy is generally considered sampling of extraprostatic tissue. This observation should be noted since it indicates that the tumor is at least pT3a in the TNM system. EPE detected on biopsy correlates well with EPE on radical prostatectomy and is usually associated with high grade and high stage disease.

For purposes of staging, seminal vesicle involvement is defined as tumor in the muscular wall of the extraprostatic portion of seminal vesicle. In a biopsy directed at the extraprostatic seminal vesicle, involvement by carcinoma indicates at least category pT3b disease. However, when seminal vesicle-type tissue is unintentionally sampled in a prostate biopsy set, it is important to be aware of some nuances. Firstly, it may be difficult to distinguish seminal vesicle from ejaculatory duct. Furthermore, the seminal vesicle tissue is likely from the intra-prostatic portion of the seminal vesicle and its involvement by tumor does not equate to pT3b disease. It is important to clarify this point in a comment so clinicians reading the report do not overstage the carcinoma.

References
G. Perineural Invasion

Perineural invasion (PNI) in needle core biopsies has been associated with EPE in some correlative radical prostatectomy studies, however, its significance as a predictor of stage and outcome is questionable in multivariate analysis.1,2,3,4,5 A recent study in targeted biopsy found PNI to independently predict extraprostatic extension.6 Studies on AS cohort showed conflicting result on the ability of PNI to predict adverse pathological findings and outcome.7,8

References

H. Atypical Intraductal Proliferation (AIP)

Atypical intraductal proliferation (AIP) is characterized by loose cribriform intraductal growth of neoplastic cells lacking significant nuclear atypia or intraluminal necrosis required for the diagnosis of IDC.1,2,3 Cribriform high-grade prostatic intraepithelial neoplasia is now regarded as AIP. Uncommonly, it may also have other architectures, but the nuclear atypia is beyond that for high grade prostatic intraepithelial neoplasia. Presence of AIP in needle core biopsy may represent an unsampled intraductal carcinoma and has been shown to be associated with adverse pathological features in radical prostatectomy.4

References
4. Shah RB, Nguyen JK, Przybycin CG, et al. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological

I. Prostatic Intraepithelial Neoplasia (PIN)
The term prostatic intraepithelial neoplasia (PIN), unless qualified, refers to high-grade PIN. Low-grade PIN is not reported. The presence of an isolated PIN (PIN in the absence of carcinoma) should be reported in biopsy specimens, especially if more than 1 site is involved. The reporting of PIN in biopsies with carcinoma is considered optional. High-grade PIN in a biopsy without evidence of carcinoma has in the past been a risk factor for the presence of carcinoma on subsequent biopsies, but the magnitude of the risk has diminished, and, in some studies, high-grade PIN was not a risk factor at all. Some studies suggest that if high-grade PIN is present in 2 or more sites, there is an increased risk of detecting carcinoma in subsequent biopsies.

References